linjc16/ctgov huggingface dataset:
Oral Glucose Tolerance Testing Using Candy for Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
The study aims to determine if a popular dextrose candy alternative yields a similar glycemic curve compared to the standard oral Dextrose solution used in the Oral Glucose Tolerance Test.

Official Title
-----------------
Oral Glucose Tolerance Testing Using Candy: A Sweet Solution to Improve Screening Compliance in Cystic Fibrosis

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Diagnostic Test: Candy Glucose Tolerance Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and Females ages 10-21 years. Cystic Fibrosis (CF) must be diagnosed. Ability to sign informed consent if they are 18 years or older. Written parental permission if age 10-17 years old. Exclusion criteria: Active CF flare as determined by the primary CF team . Use of steroids. Inability to tolerate oral feedings. Prior intestinal surgery. Concern for allergy or intolerance to dextrose, fructose, or corn derivatives.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br>All 10 participants will go through the experimental arm receiving the dextrose candy oral glucose tolerance test. | Diagnostic Test: Candy Glucose Tolerance Test<br>* Participants will use a popular dextrose candy alternative to help assess glycemic response.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic Response | The investigators will obtain glucose values at standard clinical times for oral glucose tolerance testing | Baseline, Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient and Parent Satisfaction | Self-rated satisfaction using the candy alternative will be assessed via survey | Day 2 |
Strain-Encoded Cardiac Magnetic Resonance Imaging for Dobutamine Stress Testing

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the diagnostic value of SENC to that provided by conventional wall motion analysis for the detection of inducible ischemia during DS-MRI.High-dose dobutamine stress magnetic resonance imaging (DS-MRI) is safe and feasible for the diagnosis of coronary artery disease (CAD) in humans. However, the assessment of cine scans relies on the visual interpretation of regional wall motion, which is subjective. Recently, Strain-Encoded MRI (SENC) has been proposed for the direct color-coded visualization of myocardial strain.

Detailed Description
-----------------
The assessment of inducible regional wall motion abnormalities during high-dose dobutamine stress magnetic resonance imaging (DS-MRI) is an established clinical method with high diagnostic and prognostic value for the evaluation of patients with coronary artery disease (CAD). However, the assessment of cine images relies on the visual interpretation of regional wall motion, which is subjective, and objective approaches for the detection of inducible ischemia with DS-MRI are still lacking. In our study Strain-Encoded-MRI (SENC) is used for the objective color-coded evaluation of regional myocardial strain during DS-MRI in patients with intermediate to high pretest probability for CAD. We anticipated that this technique would exhibit enhanced sensitivity for the detection of anatomically significant CAD compared to conventional wall motion reading, with invasive coronary angiography used as the standard reference.

Official Title
-----------------
Strain-Encoded Cardiac Magnetic Resonance Imaging as an Adjunct for Dobutamine Stress Testing.

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected or known coronary artery disease Exclusion Criteria: General contraindication for a dobutamine stress or for an MRI examination Age < 18 yrs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with suspected or known stable coronary artery disease | |
| 2<br>Healthy subjects as a control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of coronary artery disease (>50% diameter stenosis) by invasive angiography |  | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long-term mortality and MACE |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
myocardial strain, Strain-Encoded MRI, dobutamine stress MRI, ischemia, strain rate reserve
Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The investigators sought to assess whether plasma myeloperoxidase (MPO) levels differ among patients with stable and unstable CAD patients and control subjects, and correlate with inflammatory and clinical risk factors such as ox-LDL, NO,leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine in the patients.

Detailed Description
-----------------
Elevation of the leukocyte enzyme myeloperoxidase (MPO) in stable coronary artery disease (CAD) patients in contrast to unstable CAD patients is controversial and its relationship with some inflammatory and noninflammatory markers such as oxidized LDL (ox-LDL) and nitric oxide (NO) in the CAD patients has not been evaluated yet. Evaluation of these relationships is the aim of the study.Also the relationships between MPO and some other inflammatory biomarker such as leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine are examined. This study includes 50 stable CAD, 50 unstable CAD patients and 50 controls. Plasma MPO, ox-LDL, leptin, adiponectin, sPLA2 levels are determined using enzyme immunoassay.Homocysteine and 3-nitrotyrosine are measured using HPLC-fluorescence method. Plasma total NO and other risk factors such as lipid profile, hypertension, smoking, diabetes mellitus and familial history of CAD are also determined in the patients. Results are statistically analysed and the association between all markers are assessed.

Official Title
-----------------
Evaluation of the Association Between Myeloperoxidase Levels and Cardiovascular Risk Factors in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable and unstable patients with angiographically documented coronary artery disease. Control subjects without angiographically documented coronary artery disease. All subjects Exclusion Criteria: Patients with recent (with in 6 month) myocardial infarction or cardiovascular events, surgery (with in 3 month), cancer and infective or inflammatory diseases were not included in the study.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stable, Unstable , control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma myeloperoxidase levels |  | 3 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical risk factors |  | 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery disease
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Study Overview
=================
Brief Summary
-----------------
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.

Official Title
-----------------
A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial

Conditions
-----------------
Hereditary Angioedema

Intervention / Treatment
-----------------
* Drug: KVD900 600 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female adolescent patient 12 to 17 years of age at the time of enrollment and during sample collection in this PK subtrial. Patient is currently participating in KVD900-302. Patient must provide signed informed consent or assent (when applicable), and a legally authorized representative (LAR) must also provide signed informed consent when applicable. Patient and LAR are willing and able to provide samples per the requirements of the protocol, including willingness to complete forms and the electronic Diary, obtain and return samples in a timely manner, and obtain samples while within the required age limit. Exclusion Criteria: Patient has a history of any bleeding disorder or currently taking any anti-coagulant or anti-platelet agent.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: KVD900 600 mg<br> | Drug: KVD900 600 mg<br>* KVD900 Tablet 600 mg (2 x 300 mg)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics - Cmax |  | Up to 6 hours after IMP administration | 
| Pharmacokinetics - Tmax |  | Up to 6 hours after IMP administration | 
| Pharmacokinetics - AUC |  | Up to 6 hours after IMP administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
KONFIDENT-S
Smartphone Use and Neck Flexion Angle

Study Overview
=================
Brief Summary
-----------------
Excessive smartphone use can disrupt your sleep, which can have a serious impact on your overall mental health. It can impact your memory, affect your ability to think clearly, and reduce your cognitive and learning skills. Encouraging self-absorption.

Detailed Description
-----------------
Persistent failed attempts to use cell phone less often. Preoccupation with smartphone use. Turns to cell phone when experiencing unwanted feelings such as anxiety or depression. Excessive use characterized by loss of sense of time. Nomophobia-an abbreviation of no-mobile-phone-phobia-is also called cell phone addiction. Symptoms include: Experiencing anxiety or panic over losing your phone. Obsessively checking for missed calls, emails, and texts.

Official Title
-----------------
The Effect of Smartphone Use on Neck Flexion Angle and Hand Grip Power Among Adolescence

Conditions
-----------------
Neck Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: volunteers using smartphone less or more than 4 hours per day Exclusion Criteria: low back pain surgeries affecting upper limps

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| participants use smartphone less than 4 hours per day<br>participants use smartphone less than 4 hours per day | |
| participants use smartphone more than 4 hours per day<br>participants use smartphone more than 4 hours per day | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the neck flexion angle | flexion angle of the neck | the neck flexion angle at day 0 | 
| the neck flexion angle | flexion angle of the neck | the neck flexion angle at day 120 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hand grip power | power of hand | power of hand at date 0 | 
| hand grip power | power of hand | power of hand at date 120 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
smartphone, neck flexion
Peri-operative Expression Analysis of Pancreatic Stone Protein in a Surgical Study Population

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to analyze the peri-operative expression of pancreatic stone protein and pancreatitis-associated protein in surgical patients following major abdominal surgery by blood samples.

Official Title
-----------------
Peri-operative Expression Analysis of Pancreatic Stone Protein and Pancreatitis-associated Protein in a Surgical Study Population

Conditions
-----------------
Patients Undergoing Major Abdominal Surgery

Intervention / Treatment
-----------------
* Other: Analysis of PSP and PAP from venous blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - >= 18 years abdominal major surgery need for post-operative ICU care Exclusion criteria: - <18 years - patients who do not agree the written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sepsis Group<br>Patients suffering from sepsis in the postoperative course after major abdominal surgery | Other: Analysis of PSP and PAP from venous blood samples<br>* to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery<br>|
| Control Group<br>Patients without suffering sepsis during postoperative follow up after major abdominal surgery | Other: Analysis of PSP and PAP from venous blood samples<br>* to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosed Infections according to the Systemic Inflammatory Response System (SIRS) Criteria of the german interdisciplinary Association of Intensive and Emergency Medicine |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensive Care Unit (ICU) stay in days |  | 2 years | 
| hospital stay in days |  | 2 years | 
| postoperative complications according to the Clavien-Dindo Classification System |  | 2 years | 
| hospital costs |  | 2 years | 
| comparisons to other known infectious parameters: c-reactive protein (CRP), procalcitonin (PCT), Interleukin 6 (IL-6), Tumor Necrosis Factor Alpha (TNF-alpha), Leucocytes |  | 2 years | 
| Bacteriaemia in the blood |  | 2 years | 
| Platelets in the blood |  | 2 years |
Creatine Supplementation and Diabetes

Study Overview
=================
Brief Summary
-----------------
Creatine supplementation is capable of improving glucose tolerance in healthy subjects. The researchers aim to investigate whether this supplement can affect metabolic control in diabetic patients.

Official Title
-----------------
Efficacy and Safety of Creatine Supplementation Combined With Exercise Training in Type 2 Diabetic Patients

Conditions
-----------------
Diabetes, Renal Function

Intervention / Treatment
-----------------
* Dietary Supplement: creatine
* Other: Exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males and females type 2 diabetic patients glycated hemoglobin between > 9% non insulin users physically inactive only metformin and/or sulfonylurea users BMI > 30 kg/m2 age of years > 50 y

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: exercise and placebo<br> | Dietary Supplement: creatine<br> <br> Other: Exercise training<br> <br> |
| Experimental: exercise and creatine<br> | Dietary Supplement: creatine<br> <br> Other: Exercise training<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glycated hemoglobin |  | three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
creatine supplementation, exercise training
Effect of Intravitreal Bevacizumab on Corneal Endothelium

Study Overview
=================
Brief Summary
-----------------
To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection

Detailed Description
-----------------
Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.

Official Title
-----------------
Effect of Intravitreal Bevacizumab on Corneal Endothelium

Conditions
-----------------
Corneal Endothelial Cell Loss

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged between 20 and 80 years old can come to regular follow up at 6 month signed written consent forms not have corneal scar, or glaucoma history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit high risk in cerebrovascular and cardiovascular diseases Pregnancy and breastfeeding can undergo confocal microspopy Exclusion Criteria: History of intraocular surgery or ocular trauma during study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal endothelium cell change after intravitreal Bevacizumab injection | Measure the corneal endothelium cell using Confoscan4-Corneal confocal microscope in patient in retinal vascular clinic before and after treat with intravitreal Bevacizumab | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the complication after intravitreal Bevacizumab injection |  | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
corneal endothelium, Bevacizumab, Intravitreal injection, Confoscan
Risk Factors Related to Metabolic Syndrome in School-aged Children Who Were Born Preterm

Study Overview
=================
Brief Summary
-----------------
This is a follow-up cohort study of 8 years old children born preterm at Seoul National University Children's Hospital in Korea from 2008-2009. The children will visit outpatient clinics for examinations regarding growth, obesity and other risk factors related to metabolic syndrome. The purpose of this study is to compare growth and risk factors of metabolic syndrome among children born preterm and children born healthy term at school age

Official Title
-----------------
Risk Factors Related to Metabolic Syndrome in School-aged Children Who Were Born Preterm

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Other: Preterm/term cohort


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Very low birth weight infants and/or born less than 32 weeks of gestation age Healthy term infants for control group Parents and children accept of participation Exclusion Criteria: Major congenital anomalies Neuromuscular disease Chromosomal anomalies Patients receiving growth hormone therapy Primary hypothyroidism

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Preterm cohort<br>Preterm infants with a gestational age less than 32 weeks or birth weight less than 1,500 g | Other: Preterm/term cohort<br> <br> |
| Term control cohort<br>Healthy term infants | Other: Preterm/term cohort<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of participants with abnormal laboratory values and/or abnormal physical status |  | at 8 years corrected age | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of participants with catch-up growth failure |  | at 8 years corrected age | 
| The number of participants with hypertension |  | at 8 years corrected age |